Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20687128 | 0.86 | NTMT1 (0.46) | NTMT1UGCG | |
| Venglustat SCHEMBL12615329 | 0.78 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL29359568 | 0.78 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL19844439 | 0.78 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615333 | 0.78 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL22144980 | 0.77 | NTMT1 (0.68) | NTMT1UGCG | |
| SCHEMBL18993502 | 0.73 | NTMT1 (0.65) | NTMT1UGCG | |
| SCHEMBL23874294 | 0.73 | NTMT1 (0.76) | NTMT1UGCG | |
| SCHEMBL21181596 | 0.73 | NTMT1 (0.63) | NTMT1UGCG | |
| Venglustat SCHEMBL31522597 | 0.72 | NTMT1 (0.83) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604518-B2 | Method of preparing glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170334903-A1 | METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2017-11-23 | — | — | US | disclosed |
| US-9682975-B2 | Method of preparing glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604518-B2 | Method of preparing glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | NTMT1 977/4885UGCG 4/4885 |
| US-20170334903-A1 | METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 977/4885UGCG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.